The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Takeda
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01763996
First received: January 7, 2013
Last updated: November 6, 2013
Last verified: November 2013
  Purpose

The purpose of this study is to assess the affect of febuxostat on coronary artery flow in patients with coronary artery disease.


Condition Intervention Phase
Coronary Artery Disease
Drug: Febuxostat
Drug: Febuxostat placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Subjects With Chronic Stable Angina: A Phase 4 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change in coronary artery flow from rest to isometric handgrip (IHG) exercise at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary artery flow will be measured using magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip exercises.


Secondary Outcome Measures:
  • Change in coronary artery cross-sectional area from rest to IHG exercise at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary artery cross-sectional area will be measured by magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip excercise.

  • Change in coronary flow velocity from rest to IHG exercise at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary flow velocity will be measured by magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip excercise.

  • Change in coronary diameter from rest to IHG exercise at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary diameter will be measured by magnetic resonance imaging (MRI) at rest and during sustained isometric (static) handgrip excercise.

  • Change in coronary artery flow following the administration of sublingual nitroglycerin at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary artery flow will be measured by magnetic resonance imaging (MRI) before and following administration of nitroglycerin under the tongue.

  • Change in coronary artery cross sectional area following the administration of sublingual nitroglycerin at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary artery cross sectional area will be measured by magnetic resonance imaging (MRI) before and following administration of nitroglycerin under the tongue.

  • Change in coronary flow velocity following the administration of sublingual nitroglycerin at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary flow velocity will be measured by magnetic resonance imaging (MRI) before and following administration of nitroglycerin under the tongue.

  • Change in coronary diameter following the administration of sublingual nitroglycerin at the end of the administration of febuxostat and placebo [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Coronary diameter will be measured by magnetic resonance imaging (MRI) before and following administration of nitroglycerin under the tongue.

  • Change in time to onset of ≥1 mm ST-segment depression during exercise treadmill test [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Continuous electrocardiography (ECG) will be performed during an exercise treadmill test to assess the onset of ST-segment depression after administration of febuxostat or placebo for 6 weeks in participants with a normal ST segment at randomization.

  • Change in maximum ST-segment depression during exercise treadmill test [ Time Frame: Baseline, Week 6 and Week 12. ] [ Designated as safety issue: No ]
    Continuous electrocardiography (ECG) will be performed during an exercise treadmill test to assess the maximum ST-segment depression after 6 weeks of febuxostat or placebo treatment in participants with a normal ST segment at randomization.

  • Percentage of participants stopping exercise treadmill test due to angina at the end of the administration of febuxostat and placebo [ Time Frame: Week 6 and Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: January 2013
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sequence 1
Febuxostat 80 mg, capsules, orally, once daily for 6 weeks, followed by Febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks.
Drug: Febuxostat
Capsules
Drug: Febuxostat placebo
Febuxostat placebo-matching capsules
Experimental: Sequence 2
Febuxostat placebo-matching capsules, orally, once daily for 6 weeks, followed by Febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks.
Drug: Febuxostat
Capsules
Drug: Febuxostat placebo
Febuxostat placebo-matching capsules

Detailed Description:

The drug being tested in this study is called febuxostat. Febuxostat is being tested to treat people who have angina. This study will look at the heart and blood flow of people who take febuxostat.

The study will enroll approximately 30 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Sequence 1: 6 weeks febuxostat followed by 6 weeks of placebo.
  • Sequence 2: 6 week placebo followed by 6 weeks of febuxostat

All participants will be asked to take one capsule at the same time each day throughout the study. All participants will be asked to record any time they have angina symptoms during the study.

This single-center trial will be conducted in the United States. The overall time to participate in this study is 16 weeks. Participants will make 7 visits to the clinic.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a serum urate ≥4.0 mg/dL.
  4. Has a history of coronary artery disease, defined as:

    1. ≥50 % stenosis of ≥1 major coronary artery confirmed by angiography; OR
    2. Documented prior MI by enzymes/ECG changes; OR
    3. Documented prior exercise or pharmacologic stress/echo myocardial imaging study positive for ischemia.
  5. Has estimated glomerular filtration rate (eGFR) ≥30 mL/min by Modification of Diet in Renal Disease (MDRD) at the screening visit.
  6. Has a change in coronary artery flow from rest to isometric handgrip exercise of less than + 10 mL/min.
  7. Is male or female and aged 18 to 85 years, inclusive.
  8. A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
  9. Is on stable (30 days prior to Screening Day-21) medication doses prescribed for any underlying medical condition (ie, hypertension, angina) and is expected to remain on stable doses throughout the study duration.
  10. Is able to take nitroglycerin for anginal symptoms during study procedures.

Exclusion Criteria:

  1. Has received any investigational compound within 30 days prior to Screening.
  2. Has received allopurinol or febuxostat in a previous clinical study or as a therapeutic agent with-in 6 months of randomization.
  3. Has gout or secondary hyperuricemia (eg, due to myeloproliferative disorder, or organ transplant) or has experienced a gout flare.
  4. Has a history of xanthinuria.
  5. Has known contraindication to magnetic resonance imaging (MRI) scanning
  6. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  7. Has a history of hypersensitivity or allergies to febuxostat or nitroglycerin.
  8. Has hemoglobin <10 g/L at Screening.
  9. Has a history or clinical manifestations of a significant medical condition that might affect his/her ability to complete the study.
  10. Has any of the following during Screening:

    1. New York Heart Association Class III or IV heart failure.
    2. Acute coronary syndrome or a coronary revascularization procedure within 2 months of Screening.
    3. Wolff-Parkinson-White syndrome.
    4. Pacemaker or implantable cardioverter defibrillator.
    5. Arrhythmias (ie, SVT, atrial fibrillation/flutter, or VT during Screening).
  11. Has a recent history (within the last 2 months prior to Screening) of acute coronary syndrome or a coronary revascularization procedure, MI, heart failure, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack.
  12. Has a contraindication for using nitrates (severe anemia, increased intracranial pressure, and those with a known sensitivity or hypersensitivity to nitroglycerin or its ingredients, or other nitrates or nitrites; concomitant use either regularly and/or intermittently, with phosphodiesterase type 5 (PDE5) inhibitors).
  13. Has unstable angina that:

    1. Occurs when the patient is at rest.
    2. Is prolonged, usually greater than 20 minutes.
    3. Occurs with increasing in intensity, duration, and/or frequency.
    4. Responds poorly to nitroglycerin (ie, does not go away after three doses of nitroglycerin or returns after the nitroglycerin helped at first).
  14. Is unable to exercise sufficiently to complete ETT due to leg claudication, arthritis, deconditioning, or associated pulmonary disease.
  15. Has severe or critical valvular disease documented by echocardiogram, or congenital heart disease.
  16. The subject has left ventricular ejection fraction (LVEF) less than 35%, as documented by echocardiogram, left ventriculogram, or gated blood pool scan..
  17. The subject has clinically significant cardiac conduction defects (ie, second- or third-degree atrioventricular block, or sick sinus syndrome) at Screening
  18. Has hypertrophic cardiomyopathy.
  19. Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level of greater than 2.0 times the upper limit of normal, has active liver disease, or jaundice.
  20. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the Screening Visit.
  21. Is required or expected to require excluded medications including digoxin or digoxin-containing compounds.
  22. If female, is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  23. Has participated in another clinical trial within the past 30 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01763996

Contacts
Contact: Takeda Study Registration Call Center 800-778-2860 medicalinformation@tpna.com

Locations
United States, Maryland
Recruiting
Baltimore, Maryland, United States
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Takeda Global Research and Development Center, Inc.
  More Information

No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01763996     History of Changes
Other Study ID Numbers: CCR-FEB-002, U1111-1136-2270
Study First Received: January 7, 2013
Last Updated: November 6, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Drug therapy

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Angina, Stable
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Angina Pectoris
Chest Pain
Pain
Signs and Symptoms
Febuxostat
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014